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unitary cost average adjusted by age-gender and Charlson-index
was increased according to CRL category: low: €986.14;
moderate: €1021.20; high: €1107.64 and very high €1328.09;
p < 0.001. These results were obtained in all analysed compo-
nents. Pharmaceutical cost represented 66.2% of the total. CON-
CLUSIONS: Subjects with high CRL showed older age, high
morbidity (diabetes, smoking, hypertension) and CRL presence,
existing gender differences (man) with high consume of sanitary
resources. There are a high margin of improvement in the
primary prevention of health, were should be established cost-
effective measures to promote intervention strategies in this
patients collective.
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OBJECTIVES: The TRITON-TIMI 38 Trial demonstrated that
in patients with acute coronary syndromes (ACS) undergoing
planned percutaneous coronary intervention (PCI), prasugrel
compared to clopidogrel signiﬁcantly reduced the rate of
ischemic events over up to 15 months of follow-up, but
increased the risk of major bleeding. We used patient-level
resource use data to estimate and compare index, follow-up and
total hospitalization costs, exclusive of study drug, for patients
treated with prasugrel vs. clopidogrel in TRITON-TIMI 38,
both in the overall trial population and among selected sub-
groups. METHODS: For the economic study for TRITON,
details regarding hospitalizations for all patients from 8 high
enrolling countries (U.S., Australia, Canada, Germany, Italy,
Spain, U.K., France; n = 3373 prasugrel, 3332 clopidogrel) were
collected prospectively. These data were used to assign DRGs to
all index and subsequent hospitalizations, to which average
2005 Medicare reimbursement rates were applied. Physician
costs associated with all hospitalizations were estimated based
on the DRG-speciﬁc ratio of physician reimbursement to hospi-
tal costs. Estimates of incremental costs associated with PCI-
associated periprocedural MIs and PCI and CABG associated
bleeding events were added separately based on published data
from similar patient populations. RESULTS: For the entire 8
country population, treatment with prasugrel was associated
with a $613 per patient mean reduction in overall hospitaliza-
tion costs, reﬂecting a $7/patient increase in index hospitaliza-
tion costs (components of which included a $38/patient increase
in costs associated with periprocedural bleeds and a $18/patient
decrease in costs resulting from a reduction in periprocedural
MI) and $620/patient reduction in follow-up cost savings due
primarily to prevention of MI and revascularization procedures.
Among the subgroup of patients (n = 5270, 79%) who had no
risk factors for increased bleeding (i.e., prior stroke or TIA, age
>75 yrs, and weight <60 kg), prasugrel was associated with a
$43/patient increase in initial hospital costs ($43/patient increase
due to periprocedural bleed and $21/patient decrease due to
periprocedurlal MI). During followup, costs associated with MI
and repeat revascularizations were $872/patient lower with pra-
sugrel, while costs associated with follow-up bleeding events
were $74/patient higher; aggregate hospitalization costs were
$637/patient lower with prasugrel for this subgroup. Among the
subgroup with 1 or more risk factors for increased bleeding,
initial hospitalization costs were lower by $130 with prasugrel
(despite an average $20 increase in costs due to periprocedural
bleeds), and overall follow-up costs were $395 lower, resulting
in aggregate savings of $525/patient. CONCLUSIONS: For ACS
patients undergoing planned PCI, the lower ischemic event rate
with prasugrel compared to clopidogrel yields a reduction in
overall hospitalization costs, despite increased costs associated
with bleeding. These ﬁndings were accentuated among the large
subgroup of patients with no risk factors for increased bleeding.
These results will have implications for the cost-effectiveness of
alternative antiplatelet strategies for ACS patients undergoing
PCI.
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OBJECTIVES: To estimate the costs to manage bleeds in hospi-
talized acute coronary syndrome (ACS) patients in Germany
treated with antithrombotics, antiplatelet, and ﬁbrinolytic thera-
pies. treated with antithrombotics, antiplatelet, and ﬁbrinolytic
therapies. METHODS: Retrospective hospital chart review of
ACS patients identiﬁed with one of following bleeds: symptom-
atic intracranial haemorrhage (IH), retroperitoneal haemorrhage
(RH), gastrointestinal haemorrhage (GH), decrease in Hb greater
or equal to 3 g/dL (DH), puncture site bleed (PS), or transfusion
of greater than or equal to 2 units of blood product. Reason for
admission, length of stay (LOS), diagnostic procedures, and
transfusion related resources were counted and costed using unit
estimates based upon German DRGs and procedures. Bleed
related LOS was calculated using the reported date of bleed until
discharge. RESULTS: Records of 61 consecutive ACS patients
were included in the study. Average age was 68.6 with 60%
males. Patients were classiﬁed as: 1 IH, 3 RH, 10 GH, 14 DH, 31
PS and 2 with transfusions. The average LOS ranged between 6
and 13.5 days but ranged up to 23 days. The average bleed-
related LOS ranged from 5 to 12 days. Average costs by type
of patient classiﬁcation were: IH €3739, RH €5467, GH €5172,
DH €3336, PS €3380, transfusions €6366. Average cost overall
patients was €3879 of which €3004 occurred after the bleed date.
LOS and resource use details allow hospitals to estimate their
own internal costs of antithrombotics, antiplatelet, and ﬁbrin-
olytic therapies. CONCLUSIONS: German hospitals are paid by
case severity and diagnosis of patients. Understanding the full
costs of managing ACS patients and avoiding bleeds may help
control hospital costs.
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OBJECTIVES: We evaluated the potential costs or cost-savings
of coronary CT angiography (CTA) in a hypothetical patient
population with varying degrees of coronary artery disease
(CAD) prevalence. METHODS: We developed a mathematical
model to evaluate the potential costs associated with coro-
nary CTA after an equivocal or non-diagnostic exercise stress
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echocardiography (stress echo), exercise stress nuclear scintigra-
phy (stress nuclear), or exercise treadmill test (ETT) study. The
model was developed to evaluate the potential cost savings of
coronary CTA vs. cardiac catheterization in patients who have an
abnormal or non-diagnostic test result. RESULTS: A strategy
utilizing coronary CTA to evaluate patients with an abnormal or
non-diagnostic stress echo, stress nuclear, or ETT study was
cost-saving compared with a conventional strategy of cardiac
catheterization for these patients, up to a CAD prevalence rate
within the study population of 33–72%, depending on the
costs assumptions used in the model. CONCLUSIONS: An
evaluation strategy that uses coronary CTA for the primary
evaluation of patients with abnormal ETT, stress echo, or stress
nuclear test may reduce costs in a patient population with a low
to intermediate prevalence of CAD.
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OBJECTIVES: Acute heart failure (AHF) is life a threatening
disease which includes variable causes and complications. The
aim was to assess clinical characteristics, medication and costs
during hospitalization in patients with AHF. METHODS:
Patients hospitalized in a cardiological dpt. of the Faculty Hos-
pital Brno in January 2005–July2007 were classiﬁed according to
the Guidelines on the diagnosis and treatment of AHF by the
European Society of Cardiology and their medication was fol-
lowed at admission and during the stay. In-patient care costs
include ﬂat rate of admission, stay and medicinal procedures.
(1€ = 25 CZK) RESULTS: In total, 1213 patients (57.5% male,
mean age 72.5 years) with AHF were analyzed. The chronic
medication involved diuretics in 51%, less than half used anti-
platelet drugs, beta-blockers and ACE-I; statins (28.3%), nitrates
(23.6%), digoxin (21.8%). Positive inotropics were indicated in
acute state: norepinephrine (20.4%), dopamine (11.4%), dob-
utamine (10%), epinephrine (9.5%) and levosimendan (4.8%).
New-onset AHF (57%) was more common than decompensated
AHF and was concerned with higher costs. AHF with mild signs
and symptoms prevailed (49.3%), pulmonary oedema and car-
diogenic shock were both in 13%. Total direct in-hospital
expenses were €4.4 million; mean in-patient cost was €3621. The
most expensive were patients in cardiogenic shock with only 3
days of hospitalization (overall mean length-of-stay 8.2 days).
The predictors of high costs were antiarrhythmic interventions
(PM and ICD; 5.9% patients) making up to 21% of total
expenses and revascularizations (coronary angiography followed
by PCI in 31.5% patients) which made 41% of total expenses.
CONCLUSIONS: The treatment of heart failure patients uses
1–2% of health care budget in developed European countries of
which 2/3 are being spent on hospitalizations. AHF hospitaliza-
tion is more frequent as the population ages (62% patients were
more than 70 years old) and is associated with poor prognosis
(in-hospital mortality 14.5%).
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OBJECTIVES: To assess clinical and economic outcomes of PCI
following the commercial availability of drug-eluting stents
(DES). METHODS: We identiﬁed all patients undergoing PCI
from 2000–2002 (pre-DES era) and from 2004—April 31, 2006
(DES era) in a large PCI registry that includes demographic,
clinical, angiographic, procedural and outcome information.
Administrative data were used to estimate length of stay (LOS)
and procedural costs, as well as cardiac hospitalization costs
during year follow-up. We used logistic and Cox proportional
hazard models to estimate the adjusted risk of adverse events
within propensity score stratum and generalized linear modeling
to predict LOS, procedural and follow-up hospitalization costs
by treatment era. RESULTS: We compared 3422 patients from
the DES era (mean age 67, 69% male) and 4303 patients from
the pre-DES era (mean age 67, 70% male). 90% of pre-DES era
patients had bare-metal stents implanted; whereas 83% of DES
era patients had DES. Adverse event rates were similar between
time periods (adjusted odds ratio for in-hospital myocardial
infarction (MI) in DES era: 0.79; 95% CI 0.62, 1.00). During a
median 22 month follow-up, the adjusted incidence of death or
MI was similar between cohorts, but follow up procedures were
reduced in the DES era (hazard ratio for target lesion revascu-
larization in DES era vs. pre-DES era: 0.58; 95% CI 0.50, 0.68).
Models predict a mean LOS reduction of 0.40 days in the DES
era and procedural cost savings of $2053 (95% bootstrapped CI
of adjusted mean difference: -2937, -1197). Follow-up cardiac
hospitalization costs were similar. CONCLUSIONS: In a large
unselected PCI cohort, the introduction of DES was associated
with improved clinical outcomes during follow-up and reduced
in-hospital costs. These data suggest costly new technologies can
be introduced into a general practice setting while maintaining
and improving patient outcomes at an incremental cost savings.
PCV69
COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM
REPAIRVERSUS OPEN SURGICAL REPAIR: NON-RUPTURED
INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN
ELECTIVE SETTING
Hayes P1, Ryan J2, Jensen M2, Harrison L2,Wyatt M3, Bradbury A4,
Brasseur P5
1Addenbrooke’s Hospital, Cambridge, UK, 2Abacus International,
Bicester, UK, 3Freeman Hospital, Newcastle upon Tyne, UK, 4University
of Birmingham, Birmingham, UK, 5Medtronic Europe Sàrl,Tolochenaz,
Switzerland
OBJECTIVES: To determine the cost-effectiveness of endovascu-
lar aneurysm repair (EVAR) versus open surgical repair (OSR)
for non-ruptured, infrarenal abdominal aortic aneurysm (AAA)
in an elective setting. The analysis was conducted for the recent
appraisal of EVAR by the National Institute for Health and
Clinical Excellence in England and Wales. METHODS: A two-
stage cost-utility model was developed from an NHS perspective
to capture the lifetime costs and health outcomes of EVAR. The
model population represented a 70-year old, ﬁt for open surgery,
with an AAA at least 5.5 cm in diameter. A decision-tree model
captured the short-term costs and health outcomes of patients
during the ﬁrst 30-days post-repair, followed by a Markov
model, with monthly cycles during the ﬁrst 24 months and yearly
cycles thereafter, until death. Clinical endpoints included mortal-
ity and complications. Primary data were derived from the EVAR
I randomised controlled trial where reported. To reﬂect current
clinical practice other sources including retrospective patient
data were used. Costs were applied from trial data and national
reference sources. A discount rate of 3.5% was applied to costs
and health outcomes. Univariate and multivariate sensitivity
analyses were performed for all parameters. An incremental cost-
effectiveness ratio (ICER) reﬂecting incremental lifetime costs per
quality adjusted life year (QALY) gained was calculated for the
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